Peanut Allergy - Palforzia treatment withdrawn from the market
It’s unbelievable that they have decided to take such a step backward. Before the therapy, the constant fear of an allergic reaction had dominated daily life (snacks from the school cafeteria, field trips, children’s birthday parties, etc.). Now the only option left is to replicate the therapy on one’s own responsibility, or to have it replicated in collaboration with a reputable clinic.
https://allergyasthmanetwork.org/news/palforzia-discontinued/
>Palforzia is the only oral immunotherapy (OIT) for food allergy approved by the U.S. Food and Drug Administration. It treats peanut allergy in children ages 1 through 17. The notice on Stallergenes Greer’s Palforzia website reads: “This voluntary discontinuation is not related to product safety, quality, or efficacy.” Palforzia earned FDA approval in 2020. It was originally developed by Aimmune. Nestle Health Science bought Aimmune and then sold Palforzia to Stallergenes Greer.
https://allergyasthmanetwork.org/news/palforzia-discontinued/
>Palforzia is the only oral immunotherapy (OIT) for food allergy approved by the U.S. Food and Drug Administration. It treats peanut allergy in children ages 1 through 17. The notice on Stallergenes Greer’s Palforzia website reads: “This voluntary discontinuation is not related to product safety, quality, or efficacy.” Palforzia earned FDA approval in 2020. It was originally developed by Aimmune. Nestle Health Science bought Aimmune and then sold Palforzia to Stallergenes Greer.